Company intelligence / Profile preview

Mellitus Health

Beverly Hills, California, United States

Ownership: Private
Development stage: Other

Overview

Mellitus Health's Insulin Insights software demonstrated a 2.4% drop in patient HbA1c at 180 days in a real-world clinic study, with patients averaging only 1.2 blood glucose readings per day. The tool is FDA-cleared and CE-marked, supported by decades of research from Dr. Mayer B. Davidson, and is proven to optimize insulin therapy and lower HbA1c with broad regimen compatibility.

Therapeutic areas: Endocrinology
Modalities: DeviceDigital health platform
Industry: Digital Health Medical Devices

Partnerships

Venice Family Clinic (clinical study site)

Beyond the preview

Go deeper on Mellitus Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mellitus Health.

Explore the full profile